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Background: Resveratrol, a naturally occurring stilbene, has been categorized as a phytoestrogen due to its ability
to compete with natural estrogens for binding to estrogen receptor alpha (ERα) and modulate the biological
responses exerted by the receptor. Biological effects of resveratrol (RES) on estrogen receptor alpha (ERα) remain
highly controversial, since both estrogenic and anti-estrogenic properties were observed.
Results: Here, we provide insight into the structural basis of the agonist/antagonist effects of RES on ERα ligand
binding domain (LBD). Using atomistic simulation, we found that RES bound ERα monomer in antagonist
conformation, where Helix 12 moves away from the ligand pocket and orients into the co-activator binding groove
of LBD, is more stable than RES bound ERα in agonist conformation, where Helix 12 lays over the ligand binding
pocket. Upon dimerization, the agonistic conformation of RES-ERα dimer becomes more stable compared to the
corresponding monomer but still remains less stable compared to the corresponding dimer in antagonist
conformation. Interestingly, while the binding pocket and the binding contacts of RES to ERα are similar to those of
pure agonist diethylstilbestrol (DES), the binding energy is much less and the hydrogen bonding contacts also
differ providing clues for the partial agonistic character of RES on ERα.
Conclusions: Our Molecular Dynamics simulation of RES-ERα structures with agonist and antagonist orientations of
Helix 12 suggests RES action is more similar to Selective Estrogen Receptor Modulator (SERM) opening up the
importance of cellular environment and active roles of co-regulator proteins in a given system. Our study reveals
that potential co-activators must compete with the Helix 12 and displace it away from the activator binding groove
to enhance the agonistic activity.
Keywords: Resveratrol, Estrogen Receptor, Agonist, Antagonist, Phytoestrogen, Helix 12, Molecular dynamics
simulation, Hydrogen bondingBackground
Resveratrol (RES) (3,5,4′-trihydroxy-trans-stilbene) is a
naturally occurring stilbene commonly found in grapes
and red wine [1]. Resveratrol has various health benefits,
such as cardiovascular, neuroprotective, anti-oxidant, anti-
inflammatory, anti-diabetic, anti-viral, and cancer prevent-
ive properties [2-7]. Resveratrol has been characterized as* Correspondence: alevenson@umc.edu; pbiswas@tougaloo.edu
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distribution, and reproduction in any mediuma phytoestrogen based on its ability to compete with 17β-
estradiol (E2) for binding to and modulating the activity of
estrogen receptor alpha (ERα) [8]. However the biological
effects of RES on ERα are still highly controversial. Experi-
mental studies performed using different cell lines and re-
porter constructs suggest that the estrogenicity of RES,
both in terms of the potency and degree of agonism de-
pends on the cell type, the specific sequence and promoter
context of the estrogen response elements (EREs), gene of
interest, ER isoforms, and the assays used [7]. Superestro-
genic properties of RES have first been reported in MCF-7
human breast cancer cells transfected with reporter-gene
constructs, [8] and then were confirmed in additional
studies with MCF7 and HepG2 cells by others [9,10]. Fullntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pressing endogenous ERα [11] and stably transfected with
wild type and mutant (D351Y) ERα [12,13]. However, in
other cell types (COS-1, kidney; BG-1, ovarian; CHO-K1,
ovarian) transfected with ERα, only partial agonism was
observed depending on the ERE-reporter [8,14,15] while
the agonistic stimulation of cell growth were observed in
two other studies in non-breast cancer cells [16,17]. In
addition, RES antagonism or “no agonism” was also re-
ported in E2-treated MCF7 cells, mammary tumor models
and in the reproductive and nonreproductive estrogen tar-
get tissues in vivo [18-22]. Altogether, RES appears to be a
mixed agonist/antagonist, a land mark feature or character-
istic of selective ER modulators (SERMs) [23-25]. The gene
expression profiling of breast cancer cells transfected with
ERα and treated with E2, RES, several SERMs and pure
antiestrogen ICI revealed substantial overlap between RES-
and SERM-induced gene modulations confirming postu-
lated mixed agonist/antagonist character of RES [24,25].
The mixed agonist/antagonist nature of RES remains of
great interest considering its potential to have an impact
on human health. While as a natural SERM, the partial es-
trogenic activity of RES could provide health benefits in
cardiovascular system, bone tissues, and Alzheimer’s dis-
ease, there is a concern for its adverse side effects if it is
used as a preventive or therapeutic agent for hormone-
dependent cancers, particularly in ERα positive breast
cancers.
Resveratrol binds to ERα and is able to compete with
classical estrogen E2 [8,14,15]. Binding of estrogenic lig-
and brings conformational changes suitable for the protein
to dimerize, recruit co-activator proteins, bind to the ERE
in the promoter region of target genes, and trigger gene
transcription [26-28]. ERα exhibits discrete ligand-specific
conformational changes: in the presence of SERM and
pure antagonist, the AF2 helix, i.e., Helix 12 adopts a
distinct conformation than the agonist bound ERα, pre-
venting the co-activator binding [29-31]. Interestingly, in
experiments with AF2 deleted mutant ERα, E2 and RES
behaved differently in their ability to regulate TGFα ex-
pression suggesting possible conformational differences in
ERα-E2 and ERα-RES complexes [13].
The structure of the RES-ER complex has not yet been
experimentally determined. Molecular modeling sug-
gested RES to form more hydrogen-bonding with ERα
than DES and thus have the potential to generate differ-
ent conformation of the protein [32,33]. However, the
resulting receptor dynamics upon RES binding has never
been explored. In the present study, we have investigated
the conformational dynamics of the ERα ligand binding
domain (LBD) monomer and dimer bound to RES using
highly suitable method of Molecular Dynamics (MD)
simulation and examined the effect of RES binding in
both classical agonist and antagonist conformations. Werefer the agonist and antagonist conformation of ERα in
terms of Helix 12 orientations as observed from the dif-
ferent ligands bound to ERα LBD crystal structures
[28-30]. Our results provide for the first time the struc-
tural reasons for antagonist and partial agonist activity
of RES exerted on ERα.Results and discussions
We used MD simulation to systematically study the effect
of RES binding to ERα LBD in monomer and homo-dimer
structures. We refer to agonist or antagonist structure in
terms of the relative orientation of helix-12 position as has
been observed in DES and 4-hydroxy tamoxifen (4-OHT)
bound crystal structures for ERα LBD [30]. When estro-
genic DES is bound to ERα LBD, helix-12 lays over the lig-
and binding pocket. However, when SERM 4-OHT is
bound to ERα LBD, helix-12 orients away from the ligand
binding pocket and lays over the co-activator binding
groove formed by residues from helices3, 4, and 5 and the
turn connecting helices 3 and 4. Schematic representa-
tions of all the four ligands (Diethylstilbestrol, Resveratrol,
4-Hydroxytamoxifen and ICI 182,780) have been shown in
Scheme 1.Effect of resveratrol binding on ERα monomers
Molecular dynamics simulations have been performed
on RES bound to both agonist and antagonist ERα LBD
monomers to gain insights into structural stability and
conformational dynamics of the protein-ligand com-
plexes and their dependency on the bound ligand sub-
types (Figure 1).
The RMSD (root means square deviations) of the back-
bone Cα atoms of the simulated protein over time can be
used to analyze the structural stability of the system. To
understand the stability of RES bound ERα-LBD com-
plexes and to compare them with ERα-LBD bound to
known agonist, antagonist, and SERM ligands, we have
performed molecular dynamics of RES bound with ERα-
LBD agonist and antagonist monomers, DES bound with
ERα-LBD agonist monomer, and 4-OHT and ICI bound
with ERα-LBD antagonist monomer. As evident from
Figure 1A, during the first 2 ns of the simulation, all the
systems undergo conformational readjustments according
to the bound ligand in the initial ERα structure and mono-
tonically tend to reach an equilibrium state. When pure
agonist (DES) or antagonist (ICI) is bound to the LBD, the
complex reaches a stable equilibrium state during simula-
tion. Resveratrol bound ERα-LBD antagonist conform-
ation also reaches a stable equilibrium state during the
simulation and its conformational dynamics is comparable
with the pure agonist DES or pure antagonist ICI bound
LBD. On the contrary, RES bound agonist ERα-LBD
shows high fluctuations over its assumed equilibrium state
Scheme 1 Chemical structures of four ERα ligands used in this study: Diethylstilbestrol, Resveratrol, 4-Hydroxytamoxifen, ICI 182,780.
Chakraborty et al. BMC Structural Biology 2013, 13:27 Page 3 of 11
http://www.biomedcentral.com/1472-6807/13/27during the simulation which is comparable to the SERM
(4-OHT) induced dynamics of ERα-LBD.
To understand the structural basis for the observed
differences in RMSD fluctuations between the RES
bound agonist and antagonist ERα-LBD conformations
during simulation, we have analysed the RMSF (root
mean square fluctuations) per residues to identify the re-
gions of high fluctuations. Results are summarized in
Figure 1B. In general, the residue fluctuations for RES
bound antagonist ERα are very comparable to the RES
bound agonist ERα complex. We found that the ob-
served high RMSD fluctuations of the RES bound ERα
agonist complex are mainly due to the long loop region
between Helix 8 and Helix 9 and N-terminal region ofFigure 1 Variation of dynamic parameters of ERα bound to different
of ERα monomer with simulation time. RES-ERantgonist, DES-ER and ICI-ER ha
RES-ERagonist and 4OHT-ER show high fluctuations (green, red). (B) RMSF pro
in agonist and antagonist conformation, respectively. The peak in fluctuatioHelix 9 (from residue 150 to 166). This region is found
to be highly flexible during the MD simulation for the
RES bound agonist ERα. In contrast, Helix 12 has been
found to be flexible in both RES bound ERα antagonist
and agonist conformations.
We then analyzed the effect of RES binding on the sec-
ondary structure profile of ERα agonist and antagonist
conformations (Figure 2). ERα essentially constituted of 12
helices and one β-strand connected by short loop regions.
Comparisons of secondary structure evolution of RES
bound agonist (Figure 2A) and antagonist (Figure 2B) ERα
reveal that the secondary structures of both the complexes
are stable during the MD simulation. As evident from
Figure 2C & D, for initial agonist conformation, there areligands obtained from MD stimulation. (A) Variations in Cα-RMSD
ve highly stable complexes during simulation (cyan, black and orange),
file of RES-ERα monomer. Black and red lines represent RES bound ERα
n corresponds to Helices 8 & 9 (residues 150 to 166).
Figure 2 Secondary structure profiles with simulation time. (A) RES-ERαagonist complex; (B) RES-ERαantagonist complex. (C) Variation of
structural content of ERα bound with RES during simulation. D: Variations of percentages of helical structures in RES-ERα complex with
simulation time.
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during simulation, on average 189 ± 4 residues maintain
their initial secondary structure. In case of RES-ERα an-
tagonist complex, the initial structure has 184 residues
with defined secondary structure and 182 ± 4 residues
maintain their secondary structure during simulation.
Thus, RES-ERα antagonist complex maintains its native
secondary structure better during the simulation than the
RES-ERα agonist complex, despite the fact that the per-
centages of helical residues are very similar in both the
complexes.
To provide a detailed insight into all the visited confor-
mations of ERα LBD during its MD simulation in the
presence of various bound ligands, RMSD matrices have
been computed, and the results are displayed in Figure 3.
In the presence of pure agonist DES and antagonist ICI in
the LBD, the structure of ERα is quite stable throughout
the simulation period. It is to be noted that for DES-ERα
complex, the MD simulation has been carried out startingfrom an agonist conformation in terms of Helix 12 pos-
ition. Most of the conformations visited during the simu-
lation are structurally very close to the initial agonist
conformation; structurally distinct conformations are less
frequently visited. The situation is in sharp contrast when
4-OHT, a SERM, is bound in the LBD. The starting con-
formation of ERα for the MD simulation is in antagonist
conformation. Throughout the simulation period, this ini-
tial antagonist conformation is much less populated and
structurally distinct conformations are more frequently
visited. While for pure antagonist ICI, the starting struc-
ture of ERα for MD simulation is in antagonist conform-
ation with respect to Helix 12 orientation and throughout
the simulation period this antagonist conformation is
highly populated and the structurally distinct conforma-
tions are very less frequently visited. This signifies that the
binding of pure antagonist ICI, maintains the initial antag-
onist conformation better than a SERM. We now present
the effect of RES on the stability of ERα conformation.
Figure 3 RMSD matrices of ERα bound with different ligands computed from MD trajectory. DES-ERα, RES-ERαantagonist and ICI-ERα
display highly stable initial conformation of the protein. On the contrary, RES-ERαagonist complex shows similarity with 4OHT-ERα where the
initial structure changes appreciably during the simulation. RMSD matrix has been computed using trajectory analysis tools available within
GROMACS packages by comparing the root mean square distances of each structure in the trajectory with respect to each other structure and
generate a bi-dimentional matrix.
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LBD, the complex undergoes some structural changes
during the initial simulation period and eventually stabi-
lizes in the remaining simulation time with an RMSD of
0.35 nm from the initial structure. This feature is also evi-
dent when pure agonist DES is bound to the LBD. On the
contrary, when RES is bound in antagonist ERα conform-
ation, the initial antagonist structure is highly stable dur-
ing the simulation and there is no structurally distinct
conformational cluster visited during the simulation.
Analysis of RES-ERα binding details and evaluation of
binding energy
We next analyzed the structure of RES bound ERα agonist
and antagonist complexes (Figure 4). As evident from the
figure, RES binds in the ligand binding site of ERα in a
similar way for both the agonist and antagonist complexes.
As mentioned earlier, the only difference in these two
complexes are the Helix 12 orientation. In the agonistcomplex Helix 12 overlay over the ligand binding cavity
while in the antagonist complex the Helix 12 orients in
the co-activator binding groove. In the agonist RES-ERα
complex, the N-terminal helical region of Helix 8 and the
linker loop between Helices 8 and 9 moves upward with
respect to the dimerization surface. We have recently
demonstrated that the essential dimerization surfaces of
ERα are mainly composed of Helix 10/11 and the C-
terminal region of Helix 9 [34,35]. Thus the upward move-
ment of the linker region between Helices 8 and 9 does
not disrupt the essential dimerization surface of the recep-
tor but may induce some perturbation therein.
Using the Linear interaction energy (LIE) method we cal-
culate the binding free energies of RES with two different
ERα conformations from the MD simulation average prop-
erties [36-40]. Lennard–Jones (LJ) and Coulomb inter-
action energies between the ligand and its environment
were computed and averaged over the last 7 ns of the























Figure 4 Structures of RES-ERα complexes obtained from MD simulation. (A) The structures of RES-ERαagonist (green) and RES-
ERαantagonist (red) are overlapped. Using VMD, the ERα is shown in New Cartoon representation, and RES is shown in VDW mode. The side
chains of some of the residues whose conformations are dramatically different between the complexes are shown: Helix12 and linker region of
Helices 8 and 9. (B) & (C) Details of the hydrogen bonding contacts between DES and RES with ERα agonist conformation, respectively. RES is
bound within the same ERα pocket that recognizes DES and 4OHT [30,32,33]. The hydrogen-bonding interactions with the different residues
are shown.
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where ELJ and ECoul denotes the LJ interaction energy and
the Coulomb interaction energy of the ligand when it is
bound to the receptor (BOUND) and it is free in solution
(FREE), respectively. The parameters α = 0.82 and β = 0.20
were used to calculate the binding energy which were
developed for ERα-ligand systems and used frequently to
calculate the binding free energy of different ligands to
ERα [39,40].Figure 5 Variations of RMSD (A) and radius of gyration, Rg (B) of RES-
represent agonist and antagonist conformation of ERα, respectively.In previous studies with cell based assays, DES is found
to have stronger binding affinity to ERα compared to es-
tradiol, but their binding energies are found to be quite
comparable: −12.55 Kcal/mol for DES and −12.40 Kcal/
mol for E2 [39]. For both DES and E2, the theoretical
binding energies calculated from AMBER force-field for a
given orientation are −10.43 Kcal/mol and −10.86 Kcal/
mol, respectively [39]. Using the LIE method as adopted
by Lipzig et al. [39] for ERα, but using the OPLS force-ERα dimer complexes with simulation time. Black and red lines
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quite comparable in ERα agonist conformation: −9.5 for
DES and −9.0 for RES. Interestingly, RES is found to bind
strongly in the antagonist conformation of ERα with the
calculated binding energy of −12.0 Kcal/mol compared
to −9.0 Kcal/mol for ERα agonist conformation. Thus, in
terms of binding energy, RES bound ERα antagonist com-
plex is energetically more favorable than RES bound ERα
agonist complex. This is an interesting revelation in the
sense that the observed energetic preferences together
with the orientational preference of Helix 12 in RES
bound ERα complex provide possible pathways for antag-
onistic actions of RES.
Analyzing several structural parameters (RMSD, sec-
ondary structure, cluster analysis) and energetics, we can
conclude that in RES bound ERα monomer, the Helix 12
preferentially orients to the co-activator binding grooves.
This orientation is markedly different compared to the
structure of ERα bound with pure agonist DES and ra-
ther similar with the conformation of ERα in presence of
SERM 4-OHT.
In addition to the energetic preferences for binding,
we further explored the details of the binding contacts
of RES within ERα ligand binding cavity (Figure 4A, B).
Figure 4A reveals that RES essentially occupies the same
binding pocket in both the agonist and antagonist con-
formations of ERα which differ in the orientation of
Helix 12. Although, as mentioned above, the orientation
of Helix 12 in RES-ERα is similar with the Helix 12
orientation in 4-OHT-ERα complex, the RES binding
pocket in ERα is very similar to that of DES. In fact, RES
forms exactly similar hydrogen bonding contacts with
eight residues as found in the case of DES binding with
ERα: LEU 346, GLU 353, LEU 391, ARG 394, MET 421,
GLY 521, HIS 524, and LEU 525 (Figure 4B & C). Inter-
estingly, ER agonists like DES and E2 contain hydroxyl
groups attached to the phenolic rings which seem crucial
for agonistic action [32]. RES also contains similar hy-
droxyl groups (one additional) attached to phenolic rings
which are involved in hydrogen bonding like in DES.
Among them, hydrogen bonding with three key residues
HIS 524, ARG 394 and GLU 353 are known to be cru-
cial to elicit the agonistic effects of DES or E2 on ERα
[32,33] and are also observed here in the complexes of
RES bound ERα. Additionally, using alanine mutation
and receptor binding studies with E2 [41], it has been
established that the residues GLY 521 and LEU 525 as-
sume key role in recognizing the agonist ligand–both
DES and RES are found to establish hydrogen bonding
with these two key residues as well. Alanine scanning
experiment revealed that while LEU 525 is crucial for
ligand binding of any type regardless of its agonist or an-
tagonist nature, HIS 524 is found to be important in the
recognition of pure agonist ligands but not so for SERMlike 4-Hydroxytamoxifen which lacks a second hydroxyl
group [41]. RES possesses hydroxyl groups attached to
two opposite benzene rings and the distal hydroxyl
group is capable of interacting with HIS 524 through
hydrogen bond. The similarity in the interaction pattern
indicates that RES has the ability to elicit similar phar-
macological effects (agonistic) on ERα like DES. How-
ever, there are explicit differences in the hydrogen
bonding pattern as well: DES provides two additional
hydrogen bonding with residues MET 343 and MET 528
while RES provides one additional hydrogen bonding
with LEU 349 residue, as shown in Figure 4B & C within
square. The interaction features of RES with ERα also
shed light on the fact that RES has a greater affinity to-
wards ERα compared to other phytoestrogens which
exhibits higher affinity towards ERβ [42-44].
Effect of RES binding on ERα-LBD dimers
Dimerization of ERα is essential for its transactivation
functions [26,28]. We have analyzed the stability of RES
binding on dimerized ERα in both agonist and antagon-
ist forms (Figure 5). As seen in Figure 5A, during the
first 3 ns of the simulation, both the systems undergo
conformational readjustments according to the bound
RES and monotonically reach an equilibrium state. Inter-
estingly, RES bound ERα dimer in both agonist and an-
tagonist dimer structures are stable during the dynamics.
Molecular dynamic simulation reveals that the RES-ERα
dimer antagonist complex is comparatively more stable
than the agonist dimer complex. The average RMSD for
the former dimer complex during the last 7 ns of simu-
lation is 0.34 ± 0.06 nm while for the later dimer com-
plex it has been observed to be 0.38 ± 0.08 nm with
respect to the initial complex, respectively. We further
analyze the stability of the dimer complex during the
simulation in terms of the radius of gyration (Rg). Rg de-
fines the overall shape and dimensions of the protein by
calculating the mass-weighted root mean square dis-
tance of a collection of atoms from their common center
of mass. The plot of the variation of radius of gyration
of each LBD dimer with time is shown in Figure 5B. It is
to be noted that we have considered two distinct confor-
mations of ERα LBD dimer. Due to the orientational
difference of Helix 12, the antagonist ERα dimer has a
higher Rg compared to the agonist form. The Rg profile
obtained from MD simulations reveals that the RES
bound ERα dimer conformation where Helix 12 takes
the classical antagonist orientation is more stable com-
pared to the complex where Helix 12 takes the agonist
conformation. In fact, the Rg values of the RES bound
agonist dimer changes and converges with the Rg value
of the antagonist ERα dimer during the simulation. Crit-
ical insight into the agonist dimer trajectory reveals that
during the simulation period Helix 12 retains in its
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Rg profile of the RES-ERα agonist dimer is solely attrib-
uted to the loop dynamics. Resveratrol bound ERα LBD
dimer in agonist conformation is more stable compared
to its monomeric form and the upward movement of
the linker region between Helices 8 and 9, as observed
for monomer, has not been observed for dimer. This can
be explained by the fact that dimerization imposes
constraints on the movement of the linker region, thus
making the agonist dimer more stable compared to its
monomeric form.
Next we have analyzed the essential dimer contacts for
RES bound agonist and antagonist dimer complexes,
shown in Figure 6A and B, respectively. As evident from
the contact map obtained from MD simulation, the re-
gions of close contact residues between the two mono-
mers are very similar for both RES bound agonist and
antagonist ERα dimers. Further analysis reveals that in
the case of antagonist dimer, the essential contacts be-
tween the two chains are more evident compared to
those in the agonist dimer.
We further analyze the interaction energies and inter-
molecular hydrogen bonding between the two mono-
mers of ERα dimer (Figure 6B, C). Resveratrol boundFigure 6 Comparison of RES-ERα dimer characteristics. (A) Left and rig
dimer, respectively. (B) Variations in Coulomb and LJ interaction energies b
7 ns of simulation. Black and red colors represents Coulomb and LJ interact
gray and cyan colors represents Coulomb and LJ interaction between two
the number of hydrogen bonds between two monomers of ERα dimer bo
conformation of ERα, respectively.antagonist ERα forms more stable dimer than the agonist
dimer (Figure 6B). Although the Coulomb interaction en-
ergies between the two monomers are very similar for both
the agonist and antagonist conformations, van der Waals
interactions are clearly more favorable in the antagonist
dimer structure. In RES bound ERα antagonist dimer the
average Coulomb and LJ interaction energies over the last
7 ns are −883.4 ± 167.7 kJ/mol and −572.2 ± 37.7 kJ/mol,
respectively. In the case of RES bound ERα agonist dimer,
the average coulomb and LJ interaction energies over
the last 7 ns are −811.7 ± 147.3 kJ/mol and −449.7 ±
40.9 kJ/mol, respectively. Analysis of the hydrogen
bonding contacts between the two monomers in the
dimer interface reveals that both the complexes have
very similar hydrogen bonding profile (Figure 6C).
Throughout the simulation period, on average about
10-12 hydrogen bonds have been observed for both RES
bound ERα agonist and antagonist dimers.
Conclusions
In the present study, we have investigated ligand-specific
responses of phytoestrogen RES on ERα LBD using mo-
lecular modeling and atomistic simulations. Our results
shed light on the structural basis of the observedht figures represent RES-ERαagonist and ERαantagonist conformation of
etween the two monomers of ERα bound with RES during the last
ion between two monomer in agonist conformation, respectively, and
monomers in antagonist conformation, respectively. (C) Variations in
und with RES. Black and red line represents agonist and antagonist
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find that RES binds at the same ligand-binding pocket of
ERα LBD that recognizes DES. To understand the struc-
tural effects of ligand-binding, we performed molecular
dynamics simulation on ligand bound ERα LBD mono-
mer and dimer complexes, and clarified the roles of
parameters such as interaction energy, conformational
energy changes, movement of the binding pocket resi-
dues, regions of high fluctuations (RMSF) and RMSD
matrix of the protein, in conformational stability and
plasticity of the receptor induced by the ligand.
When RES is bound to the agonist form of ERα, the
dimer complex is more stable compared to its monomeric
form and the upward movement of the linker region be-
tween Helix 8 and Helix 9, as observed for monomer, was
not found for dimer. However, the binding of RES to ERα
LBD monomer and dimer in antagonist conformation
makes the complex more stable with higher binding en-
ergy than RES binding to ERα LBD agonist conformation.
For ERα LBD agonist conformation, although RES binding
interactions (binding pocket and hydrogen bonding inter-
actions) is very similar to the binding feature of known
agonist DES, the binding energy is much lower for RES
than with DES and E2. This observation can explain par-
tial estrogenecity of RES; to induce agonistic effects, po-
tential co-activators have to displace the Helix 12 into an
“agonist” conformation by directly competing with more
preferable Helix 12 “antagonistic” orientation. Our results
on RES–ERα complex are very similar to the genistein
bound ERβ complexes where the relative free energies for
the agonist and antagonist conformations of Helix-12 are
similar with the “antagonist-like” state being slightly more
stable [45]. In addition, in terms of Helix 12 orientation
for agonist and antagonist conformations and the overall
conformation plasticity during simulation, RES-ERα is
markedly different from DES-ERα and rather shares char-
acteristics with 4-OHT-ERα complex. It is known that the
tissue selective agonism/antagonism of SERMs and phy-
toestrogens are the result of numerous factors, including
structure of the ligand, over-expression of ER, availability
of certain cellular proteins, balance of co-activators and
co-repressors, to mention some [12,13,46-50]. This situ-
ation might occur when due to manipulations of endo-
crine therapy in breast cancer, estrogen levels, status of
the receptor and cellular proteins are changes. Adjusting
the balance between ligand-mediated structural perturba-
tions of the ERα and tissue-specific cellular proteins will
provide an adequate strategy for the use of RES in clinic.
Methods
Modeling of the receptor-resveratrol complex
The crystal structure of ERα LBD homo-dimer (PDB ID:
3ERD) where each monomer is bound with an agonist lig-
and DES was considered as ERα LBD agonist conformation.In this structure, Helix 12 is positioned over the ligand
binding cavity such that co-activator binding pocket in the
LBD remains unperturbed. On the other hand, the crystal
structure of ERα LBD (PDB ID 3ERT) where a SERM, 4-
hydroxytamoxifen (4-OHT), is bound to the LBD and the
Helix 12 positioned itself in such a way that prevents co-
activator binding, was considered for ERα antagonist con-
formation. Molecular docking using AutoDock 4.2 [51]
was used to dock RES in both the agonist and antagonist
conformation of ERα LBD. All the hetero atoms were
deleted and non-polar hydrogens were merged for each
receptor as required by AutoDock. The Kollman united-
atom charge model was applied to the protein. Atomic
solvation parameters and fragmental volumes were added
to the protein. Resveratrol structure was obtained from
the PUBCHEM chemical library (CID 445154). Rotatable
bonds were assigned and non-polar hydrogens were
merged for the ligand. For docking, the Partial atomic
charges for the ligand were calculated using the Gasteiger-
Marsili method.
Grid maps were generated by using the empirical free-
energy scoring functions. A grid box of 120 × 120 × 120
grid points with a grid-point spacing of 0.375 Å was
considered for docking. The box was centered such that
it covered the entire LBD. 250 docking runs were per-
formed and for each run, a maximum of 2,500,000 GA
operations were carried out on a single population of
150 individuals. The default parameters of 0.8, 0.02 and
1 are used for crossover, mutation, and elitism weights,
respectively. The lowest energy docked complexes of
each ERα LBD monomer with RES was selected to build
the dimer based on the ERα LBD dimer crystal structure
(PDB ID: 3ERD) as a template. The modeled ERα LBD
dimer complexed with ligand was then solvated, energy
minimized, and appropriately relaxed with position re-
strained equilibration at 300 K to prepare for molecular
dynamic simulations.
To prepare ERα LBD bound with pure antagonist ICI
182,780, (referred as ICI throughout the text), antagonist
crystal structure 3ERT.pdb for the receptor has been
used for molecular docking of ICI employing AutoDock
4.2 and a similar docking protocol as mentioned above.
Molecular dynamics simulation
The parameters for the molecular dynamics simulation
of RES, DES, 4-OHT and ICI were developed according
to the OPLS force-field [52]. Each atom of RES molecule
was assigned the proper atom type definition as per the
OPLS-AA parameter set. The van der Waals and tor-
sional parameters and the atomic partial charges for the
ligand were obtained by group analogy in the OPLS-AA
set. The atomic partial charges are readjusted to main-
tain the charge neutrality of the whole molecule. The pa-
rameters are tested by comparing the GROMACS
Chakraborty et al. BMC Structural Biology 2013, 13:27 Page 10 of 11
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minimized structures obtained from plane wave based
DFT calculations using CPMD [55].
Each ERα LBD monomer and the dimer complex were
subjected to a preliminary short energy minimization in
vacuo using the steepest descent algorithm. Then the sys-
tem was solvated with SPC explicit water model in a cubic
box with periodic boundary condition. The box dimension
was chosen such that all the protein atoms were at a dis-
tance equal to or greater than 1 nm from the box edges.
The ionization state of the residues were set to be consist-
ent with neutral pH and Na+ ions were added to make the
system charge-neutral. The solvated system was then sub-
jected to a second energy minimization with 500 steps of
steepest descent algorithm to eliminate any bad contacts
with water. After that, a 500 ps position restrained dynam-
ics was carried out where the complex was restrained by
restraining forces while the water molecules were allowed
to move freely. It was then followed by 200 ps of NVT
simulation at 300 K and 200 ps of NPT simulation to
achieve proper equilibration of the system to be simulated.
Final production simulations were performed in the
isothermal-isobaric (NPT) ensemble at 300 K, using an ex-
ternal bath with a coupling constant of 0.1 ps. The pres-
sure was kept constant (1 bar) by using pressure coupling
with the time-constant set to 1 ps. The LINCS [56] algo-
rithm was used to constrain the bond lengths involving
hydrogen atoms, allowing the use of 2.0 fs time step. The
Van der Waals and Coulomb interactions were truncated
at 1.4 nm and the SHIFT algorithm as implemented in
GROMACS has been used to minimize the error from
truncation. The trajectories were stored at every 5 ps.
Structural analysis were carried out by using the in-
built tools of GROMACS and the secondary structure
assignments were carried out with DSSP [57] module in-
tegrated with GROMACS. The RMSD matrices were
computed on each of the trajectories by the least square
fitting of main-chain atoms and the matrices were then
processed to extract clusters of similar conformations.
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